Details
Eiromidin Indications
- peripheral nervous system diseases - mono- and polyneuropathy, myasthenia gravis and the myasthenic syndrome of various etiologies;
- CNS diseases: bulbar paralysis and paresis; recovery period of organic CNS lesions that are accompanied by motor disabilities;
- memory disorders of various origins (Alzheimer's disease and other forms of dementia in the elderly), mental retardation in children;
- complex therapy of multiple sclerosis and other forms of demyelinating diseases of the nervous system;
-intestinal atony.
Dosage & Administration
The dose and duration of treatment is determined individually depending on the severity of the disease.
In diseases of the peripheral nervous system: mono- and polyneuropathy of various origins - 5-15 mg 1-2 times a day. The course of treatment - 10-15 days (in severe cases - up to 30 days), then treatment continues tablet form of the drug.
Myasthenia gravis and myasthenic syndrome - 5-30 mg 1-3 times a day, with a further transition to tablet form. The total course of treatment - 1-2 months. If necessary, treatment can be repeated several times with a break between courses of 1-2 months.
CNS Diseases
Bulbar paralysis and paresis - 5-15 mg 1-2 times a day, a course of treatment - 10-15 days, with the possibility of further switching to tablet form.
The recovery period with organic lesions of the central nervous system - 10-15 mg 1-2 times a day, a course of treatment - up to 15 days, followed by the possibility of 1-2 times a day.
Contradictions
Hypersensitivity to ipidacrine, epilepsy, extrapyramidal disorders with hyperkinesis, angina pectoris, bradycardia, asthma, vestibular disorders, mechanical intestinal obstruction or urinary tract, gastric ulcer and duodenal ulcers during pregnancy and lactation.